E Fund Management Co. Ltd. Has $266,000 Position in Boston Scientific Co. (NYSE:BSX)

E Fund Management Co. Ltd. increased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 17.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,607 shares of the medical equipment provider’s stock after acquiring an additional 683 shares during the period. E Fund Management Co. Ltd.’s holdings in Boston Scientific were worth $266,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. National Pension Service boosted its position in shares of Boston Scientific by 2.8% during the 4th quarter. National Pension Service now owns 3,015,395 shares of the medical equipment provider’s stock valued at $174,320,000 after acquiring an additional 81,945 shares in the last quarter. Picton Mahoney Asset Management lifted its holdings in Boston Scientific by 20.1% during the 4th quarter. Picton Mahoney Asset Management now owns 298,042 shares of the medical equipment provider’s stock valued at $17,230,000 after purchasing an additional 49,856 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Boston Scientific by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,694,726 shares of the medical equipment provider’s stock valued at $444,832,000 after purchasing an additional 51,892 shares during the last quarter. Apollon Wealth Management LLC lifted its holdings in Boston Scientific by 78.5% during the 4th quarter. Apollon Wealth Management LLC now owns 20,723 shares of the medical equipment provider’s stock valued at $1,198,000 after purchasing an additional 9,111 shares during the last quarter. Finally, Machina Capital S.A.S. bought a new position in Boston Scientific during the 4th quarter valued at about $1,072,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Boston Scientific news, Director Charles J. Dockendorff sold 3,946 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total value of $286,874.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 3,946 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The disclosure for this sale can be found here. Insiders have sold 82,330 shares of company stock valued at $5,682,434 in the last three months. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Robert W. Baird lifted their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a report on Thursday, April 25th. Wells Fargo & Company boosted their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. JPMorgan Chase & Co. boosted their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Needham & Company LLC boosted their target price on shares of Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Argus boosted their target price on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.09.

Boston Scientific Stock Up 1.9 %

Shares of BSX traded up $1.38 during midday trading on Thursday, hitting $74.10. The stock had a trading volume of 6,134,504 shares, compared to its average volume of 6,590,729. The firm has a market cap of $108.71 billion, a price-to-earnings ratio of 62.27, a price-to-earnings-growth ratio of 2.51 and a beta of 0.77. The company has a 50 day simple moving average of $68.79 and a two-hundred day simple moving average of $61.81. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.